Nextcure Inc. (NXTC) NASDAQ
$1.51 (0.13) (-7.93%)
Market Cap: $42.13M
As of 04/17/24 04:00 PM EDT. Market closed.
Nextcure Inc. (NXTC)
NASDAQ
$1.51
(0.13) (-7.93%)
Market Cap: $42.13M
As of 04/17/24 04:00 PM EDT. Market closed.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel ... read more
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Heller Kevin N. | Chief Medical Officer | Jul 14, 2020 | Option Exercise | $1.77 | 27,229 | 48,195 | 49,011 | Jul 16, 2020, 04:51 PM |
| Liu Linda | SVP, Research | Nov 27, 2019 | Option Exercise | $0.75 | 55,234 | 41,656 | 55,234 | Feb 21, 2020, 04:11 PM |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | Nov 15, 2019 | Buy | $36.75 | 150,000 | 5,512,500 | 2,671,856 | Nov 19, 2019, 09:47 PM |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | May 13, 2019 | Buy | $15.00 | 400,000 | 6,000,000 | 2,521,856 | May 15, 2019, 05:59 PM |
| SHANNON TIMOTHY M | Director | May 13, 2019 | Buy | $15.00 | 50,000 | 750,000 | 2,254,442 | May 13, 2019, 07:33 PM |
| Khuong Chau Quang | Director | May 13, 2019 | Buy | $15.00 | 350,000 | 5,250,000 | 2,711,013 | May 13, 2019, 07:32 PM |
| Xu Stella | Director | May 13, 2019 | Buy | $15.00 | 125,000 | 1,875,000 | 1,103,570 | May 13, 2019, 07:32 PM |
| CANAAN X L.P. | 10% Owner | May 13, 2019 | Buy | $15.00 | 50,000 | 750,000 | 2,254,442 | May 13, 2019, 07:32 PM |
| ORBIMED ADVISORS LLC | Director | May 13, 2019 | Buy | $15.00 | 350,000 | 5,250,000 | 2,711,013 | May 13, 2019, 07:32 PM |
| Owner | Relationship | Date | Value($) |
| Heller Kevin N. | Chief Medical Officer | 07/14/2020 | 48,195 |
| Liu Linda | SVP, Research | 11/27/2019 | 41,656 |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | 11/15/2019 | 5,512,500 |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | 05/13/2019 | 6,000,000 |
| SHANNON TIMOTHY M | Director | 05/13/2019 | 750,000 |
| Khuong Chau Quang | Director | 05/13/2019 | 5,250,000 |
| Xu Stella | Director | 05/13/2019 | 1,875,000 |
| CANAAN X L.P. | 10% Owner | 05/13/2019 | 750,000 |
| ORBIMED ADVISORS LLC | Director | 05/13/2019 | 5,250,000 |
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1,268,013 | 0.04% | -53.23% | Other |
| BLACKROCK INC. | 890,102 | 0.00003% | -0.89% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 293,315 | 0.00052% | 17.23% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 174,707 | 0.00002% | No change | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View